Prognosis of the metastatic prostatic carcinoma and analyze the relative factors

Fenghong CAO; Xuefei DING; Liguo ZHANG; Xiaoqiang LI; Shaosan KANG; Xiaohai GUAN; Weixing GAO.
Chinese Journal of Urology ; (12): 838-840, 2009.
Artículo en Zh | WPRIM | ID: wpr-392225

Documentos relacionados

  1. [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)].
  2. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
  3. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
  4. [A clinical study of prostatic carcinoma].
  5. [Treatment of newly diagnosed stage D2 prostatic carcinoma with hormonal therapy alone, or chemotherapy agents in combination with hormones].
  6. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
  7. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.